What is William Blair's Estimate for APLT FY2025 Earnings?

Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) - Research analysts at William Blair raised their FY2025 earnings estimates for shares of Applied Therapeutics in a research note issued to investors on Wednesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.64) per share for the year, up from their previous estimate of ($0.66). The consensus estimate for Applied Therapeutics' current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics' FY2026 earnings at ($0.71) EPS.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last issued its quarterly earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.61 million.

APLT has been the topic of several other research reports. Wall Street Zen upgraded shares of Applied Therapeutics to a "sell" rating in a report on Thursday. Royal Bank of Canada restated a "sector perform" rating and issued a $1.50 price objective on shares of Applied Therapeutics in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $6.10.

Applied Therapeutics Price Performance

NASDAQ:APLT traded down $0.00 during midday trading on Monday, hitting $0.41. The company's stock had a trading volume of 1,900,676 shares, compared to its average volume of 3,364,237. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The firm's 50 day moving average is $0.42 and its 200-day moving average is $1.60. The firm has a market cap of $58.03 million, a P/E ratio of -0.25 and a beta of 2.00.

Institutional Investors Weigh In On Applied Therapeutics

Several hedge funds have recently bought and sold shares of APLT. Hennion & Walsh Asset Management Inc. boosted its position in Applied Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company's stock worth $268,000 after purchasing an additional 47,983 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock valued at $35,000 after buying an additional 25,601 shares in the last quarter. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics during the 4th quarter valued at approximately $35,000. Swiss National Bank purchased a new position in shares of Applied Therapeutics during the 4th quarter valued at approximately $126,000. Finally, Intech Investment Management LLC lifted its position in shares of Applied Therapeutics by 176.1% during the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock valued at $45,000 after buying an additional 33,567 shares in the last quarter. Hedge funds and other institutional investors own 98.31% of the company's stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.